Isogenica announces multimillion-pound agreement with recently nasdaq listed BioNTech SE
Isogenica multi-target, multi-year collaboration and license agreement with BioNTech SE
Isogenica has entered into a multi-target, multi-year partnership with BioNTech. The partnership follows hot on the heels of BioNTech’s €350 million fund raise and Summer 2019 IPO, the third largest IPO for a European Biotech. The funding is expected to propel several of BioNTech’s clinical and preclinical assets into the later stages of development. BioNTech is pursuing an ambitious growth strategy based on several proprietary drug modalities including antibody-drug conjugates, cell therapy and multi-specific antibody therapeutics.
Isogenica’s versatile single domain platform, LlamdA, will be deployed in VHH therapeutic antibody discovery. The antibodies are to be incorporated into BioNTech’s modalities which are destined for the clinic in immuno-oncology. This is a truly collaborative partnership, combining Isogenica’s expertise and maximising on BioNTech’s in-house discovery efforts through licensing of the LlamdA library. Under the terms of the multimillion-pound agreement, Isogenica is eligible to receive an upfront payment, research funding and licence fees, as well as preclinical, clinical and sales milestones on LlamdA™ antibody-based therapeutics deriving from the collaboration.
“This is a truly collaborative partnership, combining Isogenica’s expertise and maximising on BioNTech’s in-house discovery efforts through licensing of the LlamdA library.”
Emma Sceats, CEO at Isogenica
Isogenica is developing LlamdA® (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. Over the last four years
Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
T +44 1799 533 680